Earnings Feed
Start Free
AN2 Therapeutics, Inc.·4

Mar 23, 7:06 PM ET

Eizen Joshua M 4

Research Summary

AI-generated summary

Updated

AN2 Therapeutics (ANTX) COO Joshua M. Eizen Receives Repriced Options

What Happened

  • Joshua M. Eizen, Chief Operating Officer and Chief Legal Officer of AN2 Therapeutics (ANTX), was reported on Form 4 to have received two derivative awards (options) and simultaneously recorded matching dispositions to the issuer on March 19, 2026. The transactions are shown as: 92,000 derivative shares (grant and disposition) and 50,150 derivative shares (grant and disposition). These actions reflect a board-approved repricing of options rather than an open-market purchase or sale of common stock.

Key Details

  • Transaction date: March 19, 2026; Form filed March 23, 2026 (filed after the 2-business-day window).
  • Repriced exercise price: $3.91 per share (footnote 1). All other option terms remain unchanged except as described in the filing.
  • Vesting: The 92,000-share option vests 25% on the 9/29/2022 anniversary with the remainder monthly over the next 36 months (footnote 2). The 50,150-share option vests 1/48 each month beginning Jan 1, 2023 (footnote 4).
  • Premium End Date: The repriced exercise price may be reverted to the original exercise price under certain conditions before the Premium End Date (earliest of Sept 19, 2027; a change in control; or the reporting person’s death/disability) (footnote 1).
  • Filing timeliness: The Form 4 was filed four days after the transaction date (appears late relative to the 2-business-day Form 4 requirement).
  • Shares owned after the transaction: Not specified in the provided filing excerpt.

Context

  • These were derivative-option transactions (A = grant/acquisition of a derivative; D = disposition to issuer). The matching grant and disposition entries, together with the footnotes stating the board approved a repricing, indicate an exchange/repricing of existing option awards rather than a cash exercise, open-market sale, or gift.
  • For retail investors: repricings adjust the strike price of options and can affect potential future dilution and executive incentives; they are not direct indications of an insider buying or selling company stock.